Skip to main content

Table 1 Demographic and clinical characteristics of patients with COVID-19

From: Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study

  Total (n = 70) Non-ICU (n = 30) ICU (n = 23) Fatality (n = 17)
Age, years 56.5 (41–73) 46 (31–65.5) 57 (44–66) 73 (63–79)
Sex, Male 46 (65.7) 20 (66.7) 13 (56.5) 13 (76.5)
Viral shedding period, days 12 (9–16.3) 9 (6–11.3) 13 (11–16) 19 (12.5–21)a
Chronic comorbidities
 Hypertension 18 (25.7) 8 (26.7) 7 (30.4) 3 (17.6)
 Diabetes 13 (18.6) 3 (10) 5 (16.7) 5 (29.4)
 Cardiovascular diseases 7 (10) 2 (6.7) 3 (13) 2 (11.8)
 Chronic kidney disease 4 (5.7) 20 3 (13) 1 (5.9)
 Respiratory system diseases 1 (1.4) 0 (0) 0 (0) 1 (5.9)
Chronic liver diseases 13 (18.6) 6 (20) 5 (16.7) 2 (11.8)
 Chronic hepatitis B 5 (7.1) 1 (3.3) 3 (13) 1 (5.9)
 Alcoholic liver disease 5 (7.1) 5 (16.7) 0 (0) 0 (0)
 Fatty liver disease 2 (2.9) 0 (0) 1 (4.3) 1 (5.9)
 Chronic hepatitis C 1 (1.4) 0 (0) 1 (4.3) 0 (0)
HBV markers     
 HBsAg/HBeAb/HBcAb (+) 5 (7.1) 1 (3.3) 3 (13) 1 (5.9)
 HBsAb/HBeAb/HBcAb (+) 38 (54.3) 10 (33.3) 15 (65.2) 13 (76.5)
 All HBV markers (−) 11 (15.7) 6 (20) 3 (13) 2 (11.8)
 Sole HBsAb (+) 7 (10) 6 (20) 0 (0) 1 (5.9)
 Sole HBcAb (+) 4 (5.7) 3 (10) 1 (4.3) 0 (0)
 HBeAb/HBcAb (+) 3 (4.3) 2 (6.7) 1 (4.3) 0 (0)
 HBsAb/HBcAb (+) 2 (2.9) 2 (6.7) 0 (0) 0 (0)
Self-medication after illness 22 (31.4) 8 (26.7) 6 (26.1) 8 (47.1)
 Traditional Chinese medicine 14 (20) 6 (6.7) 4 (17.4) 4 (23.5)
 Acetaminophen 4 (5.7) 2 (6.7) 1 (4.3) 1 (5.9)
 Levofloxacin/Moxifloxacin 4 (5.7) 0 (0) 1 (4.3) 3 (17.6)
Treatment during hospitalization     
 Symptomatic treatment 62 (88.6) 22 (73.3) 23 (100) 17 (100)
 Antiviralsb 56 (80) 20 (66.7) 19 (82.6) 17 (100)
 Antibioticsc 36 (51.4) 8 (26.7) 11 (47.8) 17 (100)
 Traditional Chinese medicine 12 (17.1) 3 (10) 5 (21.7) 4 (23.5)
 Immunoglobulin 20 (28.6) 0 (0) 7 (30.4) 13 (76.5)
 Glucocorticoid 17 (24.3) 0 (0) 5 (21.7) 12 (70.6)
 High-flow oxygen 35 (50) 0 (0) 18 (78.3) 17 (100)
 Mechanical ventilation 17 (24.3) 0 (0) 3 (13) 14 (82.4)
 CRRT 11 (15.7) 0 (0) 0 (0) 11 (64.7)
  1. Data are presented as median (interquartile range) or n (%)
  2. aThe viral shedding period in the fatality group was calculated from the beginning of detectable SARS-CoV-2 to the discontinuation of viral shedding or to the death date, even though viral shedding continued at the time of fatality
  3. bAntiviral agents mainly included oseltamivir, interferon α (aerosol inhalation), and lopinavir/ritonavir
  4. cAntibiotics mainly included levofloxacin and moxifloxacin for all groups and meropenem, biapenem, vancomycin, and tigecycline for the fatality group
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us